Olema Pharmaceuticals (OLMA) said Friday that the OP-3136 molecule, which selectively inhibits lysine acetyltransferase 6 in prostate, ovarian, and non-small cell lung cancer models, has shown anti-tumor activity in preclinical studies.
The OP-3136 molecule showed potent anti-proliferative activity in multiple ovarian, NSCLC and prostate cell lines in vitro during the studies. It showed activity that was independent of KAT6 amplification or over expression, and demonstrated anti-tumor activity in vivo xenograft models of ovarian, NSCLC and prostate cancers.
The results indicate that this treatment could be effective in treating these types of tumors in addition to breast cancer, according to the announcement.
The biopharmaceutical company said it will present the preclinical data at the American Association for Cancer Research annual meeting in Chicago, Illinois, happening between April 25 and April 30.
The FDA cleared the investigational new drug application for OP-3136 in December 2024. Currently, patients are enrolling in the phase 1 clinical trial of OP-3136, the company said.
Price: 4.94, Change: -0.16, Percent Change: -3.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。